Watching Vericel Corp.; J Capital Research Issues Short Report On Co
Portfolio Pulse from Benzinga Newsdesk
J Capital Research has issued a short report on Vericel Corp. (VCEL), a biopharma company that specializes in cartilage-repair and burn treatment products. The report criticizes VCEL for its continuous losses since 1996, with the exception of a small profit in 2020, and its failure to deliver on promises of new applications for its products. The report also highlights the limited growth potential of VCEL's products due to high costs and limited patient populations. Despite the company's losses, management has been rewarded with substantial share compensation.
September 20, 2023 | 2:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Vericel Corp. is under scrutiny by J Capital Research for its continuous losses and limited growth potential. The company's management has been criticized for receiving substantial share compensation despite the company's performance.
The negative report from J Capital Research criticizes Vericel Corp.'s financial performance, limited growth potential, and management compensation. This could negatively impact investor sentiment and potentially lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100